Steatotic Liver Disease and the “Point of No Return” in the Development of Metabolic Disorders

We read with interest the article by Kamada et al. 1, which demonstrated that steatotic liver disease (SLD) precedes type 2 diabetes mellitus (T2D), hypertension, and dyslipidemia, independent of obesity 1. In this study, steatotic liver disease (SLD) refers to ultrasonographically detected hepatic steatosis, which includes individuals with and without overt metabolic dysfunction and overlaps with what is currently termed metabolic dysfunction-associated steatotic liver disease (MASLD). Their 7-year longitudinal study supports the concept that SLD is not merely a consequence but also an upstream driver of metabolic disorders. At baseline, the prevalence of SLD was 60.9%, exceeding that of T2D (38.2%) and hypertension (26.6%). This finding suggests that hepatic steatosis often precedes clinically manifest metabolic disorders and may serve as a readily detectable early marker during routine health checkups. Several points warrant further discussion. In this study, SLD was assessed using binary classification based on abdominal ultrasonography. Although conventional sonographic features are not fully quantitative, semiquantitative grading (e.g., mild, moderate, or severe) may better capture the hepatic fat burden and refine risk stratification for future metabolic events. Such pragmatic scoring could also serve as a practical bridge toward more quantitative modalities, including CAP or MRI-PDFF, in health check-up settings. The lack of analysis of changes in body weight is also notable as categorizing by weight change (loss/stable/gain) and comparing incident metabolic outcomes within SLD strata, together with testing an SLD-by-weight-change interaction, could clarify which subgroups benefit most from weight reduction; for example, whether the metabolic benefit of weight loss differs according to SLD persistence or regression. Although the incidence of metabolic outcomes was lower in individuals with SLD regression, 50.8% still developed T2D and 37.3% developed hypertension, showing that a history of SLD may identify a persistently high-risk phenotype for developing metabolic diseases. Although the present design cannot disentangle irreversible metabolic programming from residual constitutional risk, our findings are compatible with the hypothesis that once the SLD–metabolic disease pathway is activated, later changes in body weight or steatosis may not fully abrogate downstream risk. This pattern may be compatible with a “point of no return,” with several nonmutually exclusive explanations: (a) a true irreversible pathophysiologic switch, (b) an apparent irreversibility due to the long interval between measurements, and (c) residual risk driven by constitutional susceptibility not fully captured by the standard clinical variables. Once metabolic diseases, such as T2D, develop, they may accelerate liver disease progression and worsen the prognosis 2. This bidirectional and self-reinforcing relationship between SLD and type 2 diabetes or broader cardiometabolic diseases, including the adverse impact of glucose intolerance on chronic liver disease outcomes 3, 4, has been emphasized in recent reviews 5, 6. Therefore, SLD should be viewed not only as a precursor but also as a pivotal target for early intervention to prevent metabolic and hepatic disease progression. Kamada et al. provided valuable evidence supporting this paradigm. Future studies incorporating higher-frequency and more quantitative assessments may further optimize preventive strategies for health checkup-based care models. The authors declare no conflicts of interest. Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.